Adaptive Biotechnologies Corp — Director's Dealing 2025

Nov 25, 2025

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Adaptive Biotechnologies Corp (ADPT)
CIK: 0001478320
Period of Report: 2025-11-20

Reporting Person: BENZENO SHARON (Chief Commercial Ofc Imm Med)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2025-11-20	Common Stock	M	133032	$8.46	Acquired	525755	Direct
2025-11-20	Common Stock	M	68961	$12.14	Acquired	594716	Direct
2025-11-20	Common Stock	S	297925	$16.54	Disposed	296791	Direct
2025-11-21	Common Stock	M	834	$6.27	Acquired	297625	Direct
2025-11-21	Common Stock	M	20834	$6.55	Acquired	318459	Direct
2025-11-21	Common Stock	M	49480	$6.55	Acquired	367939	Direct
2025-11-21	Common Stock	M	34375	$7.27	Acquired	402314	Direct
2025-11-21	Common Stock	M	119809	$12.14	Acquired	522123	Direct
2025-11-21	Common Stock	M	83145	$3.99	Acquired	605268	Direct
2025-11-21	Common Stock	S	308477	$16.91	Disposed	296791	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2025-11-20	Stock Option (right to buy)	$8.46	M	133032	Disposed	2033-03-06	Common Stock (133032)	Direct
2025-11-20	Stock Option (right to buy)	$12.14	M	68961	Disposed	2032-03-04	Common Stock (68961)	Direct
2025-11-21	Stock Option (right to buy)	$6.27	M	834	Disposed	2027-04-25	Common Stock (834)	Direct
2025-11-21	Stock Option (right to buy)	$6.55	M	20834	Disposed	2028-02-07	Common Stock (20834)	Direct
2025-11-21	Stock Option (right to buy)	$6.55	M	49480	Disposed	2028-10-01	Common Stock (49480)	Direct
2025-11-21	Stock Option (right to buy)	$7.27	M	34375	Disposed	2029-02-07	Common Stock (34375)	Direct
2025-11-21	Stock Option (right to buy)	$12.14	M	119809	Disposed	2032-03-04	Common Stock (119809)	Direct
2025-11-21	Stock Option (right to buy)	$3.99	M	83145	Disposed	2034-03-04	Common Stock (83145)	Direct

Footnotes

F1: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 18, 2025.

F2: The options vested with respect to 1/4 of such shares on March 6, 2024, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F3: The options vested with respect to 1/4 of such shares on March 4, 2023, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F4: The options vested with respect to 1/4 of such shares on April 19, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F5: The options vested with respect to 1/4 of such shares on November 1, 2018, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F6: The options vested with respect to 1/4 of such shares on October 1, 2019, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F7: The options vested with respect to 1/4 of such shares on January 1, 2020, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F8: The options vested with respect to 1/4 of such shares on March 4, 2025, with 1/48 of such shares vesting thereafter at the end of each full month of continuous service until fully vested.

F9: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $16.90, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.

F10: The price reported for this transaction is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.50 to $17.44, inclusive. The reporting person undertakes to provide to Adaptive Biotechnologies Corporation, any security holder of Adaptive Biotechnologies Corporation, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in any footnotes to this Form 4.